PROMOMED Company announces the beginning of a new stage of clinical study of Esperavir®.[1] In June 2026, a multicenter prospective post-registration study of ESPERANCE was launched, which will take place in real clinical practice. Its main goal is to collect up—to-date data on the effectiveness and safety of the drug in the current epidemiological conditions.

Influenza and ARVI viruses are constantly evolving, and the main reason for the intensity of mutations lies in their molecular "engine" — RNA polymerase. This enzyme is a key component of the replicative complex responsible for the synthesis of viral RNA, the carrier of the virus' genetic information. It provides rapid genome replication, which leads to the appearance of various variants of the virus within a single host. Such variability dictates the need to timely confirm the effectiveness and safety of drugs in current epidemiological conditions.

Esperavir® acts on this process: the drug suppresses the reproduction of the virus by disrupting the work of RNA polymerase, which creates new viral particles. RNA polymerase is a superconservative enzyme, meaning it cannot be mutated. Therefore, the drug works regardless of the strain of the virus and the variability of viral particles.

Recently, the Russian Ministry of Health officially approved the use of the drug not only for COVID-19, but also for other acute respiratory infections caused by RNA viruses. Studying the drug in the format of real clinical practice will strengthen the evidence base and give doctors and patients more confidence when using it.

ESPERANCE's research is non-interventional. This means that doctors maintain standard treatment regimens and monitor the condition of patients who receive therapy as usual.

The project will involve patients over the age of 18 with a confirmed diagnosis of influenza or acute respiratory viral infections, provided there are no contraindications to the use of the drug. The study will last until September 2026 and will be conducted simultaneously in several clinical centers, which increases the representativeness of the results.

It will cover the summer and early autumn seasons, when the activity of respiratory viruses remains quite high. The results of the ESPERANCE program will help expand the evidence base, which gives doctors the opportunity to make more informed decisions when prescribing therapy. For the Company, this means strengthening the position of the drug in the market and fulfilling the main task — to timely confirm the effectiveness and safety of the drug in the current epidemiological conditions.

[1] This drug is a prescription drug and should be purchased only as prescribed by a doctor. The drug has contraindications. Please read the instructions for use. Do not use the drug unless it has been prescribed to you by your doctor. When using the drug, always follow the instructions for use and the recommendations of your doctor.